KR20200003067A - 진단용 최종 당화 산물 항체 - Google Patents

진단용 최종 당화 산물 항체 Download PDF

Info

Publication number
KR20200003067A
KR20200003067A KR1020197035140A KR20197035140A KR20200003067A KR 20200003067 A KR20200003067 A KR 20200003067A KR 1020197035140 A KR1020197035140 A KR 1020197035140A KR 20197035140 A KR20197035140 A KR 20197035140A KR 20200003067 A KR20200003067 A KR 20200003067A
Authority
KR
South Korea
Prior art keywords
age
cell
patient
cells
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197035140A
Other languages
English (en)
Korean (ko)
Inventor
루이스 에스. 그루버
Original Assignee
시와 코퍼레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시와 코퍼레이션 filed Critical 시와 코퍼레이션
Priority to KR1020237044845A priority Critical patent/KR20240006702A/ko
Publication of KR20200003067A publication Critical patent/KR20200003067A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7042—Aging, e.g. cellular aging

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
KR1020197035140A 2017-05-04 2018-05-03 진단용 최종 당화 산물 항체 Ceased KR20200003067A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237044845A KR20240006702A (ko) 2017-05-04 2018-05-03 진단용 최종 당화 산물 항체

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762501424P 2017-05-04 2017-05-04
US62/501,424 2017-05-04
US201762610003P 2017-12-22 2017-12-22
US62/610,003 2017-12-22
PCT/US2018/030931 WO2018204679A1 (en) 2017-05-04 2018-05-03 Diagnostic advanced glycation end-product antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237044845A Division KR20240006702A (ko) 2017-05-04 2018-05-03 진단용 최종 당화 산물 항체

Publications (1)

Publication Number Publication Date
KR20200003067A true KR20200003067A (ko) 2020-01-08

Family

ID=62223287

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197035140A Ceased KR20200003067A (ko) 2017-05-04 2018-05-03 진단용 최종 당화 산물 항체
KR1020237044845A Ceased KR20240006702A (ko) 2017-05-04 2018-05-03 진단용 최종 당화 산물 항체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237044845A Ceased KR20240006702A (ko) 2017-05-04 2018-05-03 진단용 최종 당화 산물 항체

Country Status (9)

Country Link
US (1) US20200150131A1 (https=)
EP (1) EP3619540A1 (https=)
JP (2) JP2020521117A (https=)
KR (2) KR20200003067A (https=)
CN (1) CN110832327A (https=)
AU (1) AU2018261622A1 (https=)
CA (1) CA3062082A1 (https=)
IL (1) IL270285B2 (https=)
WO (1) WO2018204679A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022216145A1 (ko) * 2021-04-09 2022-10-13 가천대학교 산학협력단 글리코톡신, 글리코톡신에 결합된 특정 단백질 또는 글리코톡신-특정 단백질 복합체를 포함하는 신경퇴행성 질환용 바이오마커

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2553225C2 (ru) 2008-05-23 2015-06-10 Сива Корпорейшн Способ облегчения регенерации
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
EP3194439B1 (en) 2014-09-19 2022-01-19 Siwa Corporation Anti-age antibodies for treating inflammation and auto-immune disorders
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
HUE058854T2 (hu) 2016-02-19 2022-09-28 Siwa Corp Módszer és készítmény a rák kezelésére, az áttétes rákos sejtek elpusztítására és a rák áttétképzõdésének megelõzésére a fejlett glikációs végtermékek (AGE) elleni antitest alkalmazásával
KR20180133452A (ko) 2016-04-15 2018-12-14 시와 코퍼레이션 신경퇴행성 질환을 치료하기 위한 항-노화 항체
JP2019518763A (ja) 2016-06-23 2019-07-04 シワ コーポレーション 様々な疾患及び障害の治療において使用するためのワクチン
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
CA3059803A1 (en) 2017-04-13 2018-10-18 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
EP3826670A1 (en) * 2018-07-23 2021-06-02 Siwa Corporation Methods and compositions for treating chronic effects of radiation and chemical exposure
US20220396841A1 (en) * 2019-12-02 2022-12-15 Viome Life Sciences, Inc. Detection and elimination of aberrant cells
KR20210101481A (ko) * 2020-02-10 2021-08-19 한국과학기술연구원 초음파 출력부를 포함하는 노화세포 제거 장치
US20230181730A1 (en) 2020-05-01 2023-06-15 Siwa Corporation Methods of treating infections
AU2021326232A1 (en) * 2020-08-11 2023-04-13 Shenzhen Protgen Ltd. Young and undamaged human serum albumin improves longevity of human
WO2022125776A2 (en) 2020-12-09 2022-06-16 Siwa Corporation Methods and compositions for treating kidney diseases
EP4388016A1 (en) 2021-08-20 2024-06-26 Siwa Corporation Methods and compositions for treating fibrotic diseases
CN114624362A (zh) * 2022-03-17 2022-06-14 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） 一种检测血清中晚期糖基化终末产物的试剂盒及其应用
CN118562721A (zh) * 2024-06-27 2024-08-30 广州市华代生物科技有限公司 一种基于全皮模型的糖化衰老模型及抗糖效果测试评价方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624804A (en) 1991-12-20 1997-04-29 The Rockefeller University Immunochemical detection of In vivo advanced glycosylation end products
US6380165B1 (en) 1997-09-19 2002-04-30 The Picower Institute For Medical Research Immunological advanced glycation endproduct crosslink
JP4012722B2 (ja) * 2001-11-22 2007-11-21 株式会社トランスジェニック カルボキシメチル化ペプチドに対する抗体
WO2009085216A2 (en) 2007-12-20 2009-07-09 Squicor Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease
RU2553225C2 (ru) 2008-05-23 2015-06-10 Сива Корпорейшн Способ облегчения регенерации
WO2010005531A2 (en) * 2008-06-30 2010-01-14 The Johns Hopkins University Methods for the detection of advanced glycation endproducts and markers for disease
EP2582293B1 (en) * 2010-06-18 2016-04-20 DiagnOptics Holding B.V. Method and apparatus for determining an autofluorescence value of skin tissue.
ES2725852T3 (es) * 2010-09-27 2019-09-27 Siwa Corp Eliminación selectiva de células modificadas por AGE para el tratamiento de la aterosclerosis
IL286427B2 (en) * 2014-01-28 2024-08-01 Mayo Found Medical Education & Res Inhibitors bcl-2 anti-apoptotic protein family members for treatment of non cancer pulmonary disease or an opthalmic disease
JP2017527580A (ja) * 2014-09-12 2017-09-21 ザ プロクター アンド ギャンブル カンパニー 老化防止スキンケア組成物及びレジメン
US10358502B2 (en) * 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
CN108431044A (zh) * 2015-10-13 2018-08-21 Siwa有限公司 抗age抗体及其使用方法
HUE058854T2 (hu) 2016-02-19 2022-09-28 Siwa Corp Módszer és készítmény a rák kezelésére, az áttétes rákos sejtek elpusztítására és a rák áttétképzõdésének megelõzésére a fejlett glikációs végtermékek (AGE) elleni antitest alkalmazásával

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022216145A1 (ko) * 2021-04-09 2022-10-13 가천대학교 산학협력단 글리코톡신, 글리코톡신에 결합된 특정 단백질 또는 글리코톡신-특정 단백질 복합체를 포함하는 신경퇴행성 질환용 바이오마커

Also Published As

Publication number Publication date
IL270285B1 (en) 2025-02-01
WO2018204679A1 (en) 2018-11-08
EP3619540A1 (en) 2020-03-11
RU2019139256A3 (https=) 2022-01-18
IL270285A (en) 2019-12-31
US20200150131A1 (en) 2020-05-14
CA3062082A1 (en) 2018-11-08
AU2018261622A1 (en) 2019-12-12
KR20240006702A (ko) 2024-01-15
IL270285B2 (en) 2025-06-01
CN110832327A (zh) 2020-02-21
JP2023098996A (ja) 2023-07-11
JP2020521117A (ja) 2020-07-16
RU2019139256A (ru) 2021-06-07

Similar Documents

Publication Publication Date Title
KR20200003067A (ko) 진단용 최종 당화 산물 항체
US11833202B2 (en) Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (AGE)
US10858449B1 (en) Methods and compositions for treating osteoarthritis
US20190315846A1 (en) Antibodies to Human Alpha-Synuclein
JP2023553247A (ja) がん診断のための組成物および方法
RU2788905C2 (ru) Диагностические антитела к конечным продуктам глубокого гликирования
US12459998B2 (en) Alpha-synuclein binding antibodies, or antigen binding portions thereof
CA2774286A1 (en) Use of immunoregulatory nk cell populations for predicting the efficacy of anti-il-2r antibodies in multiple sclerosis patients
HK40029952A (en) Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age)
HK40029952B (en) Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age)
HK40020584A (en) Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
HK40015192A (en) Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
HK40015176A (zh) 抗lilrb3抗体及其使用方法
HK1256931B (en) Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age)

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191127

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210503

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220906

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230726

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220906

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I